Cargando…
Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer
The role of histone deacetylases (HDACs) in lung cancer has been extensively studied. Inhibition of HDAC activities have been used as a new cancer treatment strategy. To date, many HDAC inhibitors have been shown to induce apoptosis and inhibit tumorigenesis. Chidamide (CS055) is a new member of HDA...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365669/ https://www.ncbi.nlm.nih.gov/pubmed/32701251 http://dx.doi.org/10.1097/CAD.0000000000000935 |
_version_ | 1783560080580411392 |
---|---|
author | Zhang, Na Sun, Pan Jin, Haizhen Yang, Yuqin Zhao, Qingya Zhou, Lin Guo, Lili Yang, Xiaohua Lu, Liming |
author_facet | Zhang, Na Sun, Pan Jin, Haizhen Yang, Yuqin Zhao, Qingya Zhou, Lin Guo, Lili Yang, Xiaohua Lu, Liming |
author_sort | Zhang, Na |
collection | PubMed |
description | The role of histone deacetylases (HDACs) in lung cancer has been extensively studied. Inhibition of HDAC activities have been used as a new cancer treatment strategy. To date, many HDAC inhibitors have been shown to induce apoptosis and inhibit tumorigenesis. Chidamide (CS055) is a new member of HDAC inhibitors. In China, Chidamide has been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma. However, the efficacy of Chidamide in non-small cell lung cancer remains unclear. In this study, we used lung cancer primary cells and investigated the effects of Chidamide combined with paclitaxel on lung cancer. We found that Chidamide combined with paclitaxel effectively inhibited the expression and activity of HDAC in primary lung cancer cells, induced their apoptosis and blocked cell cycle. Chidamide combined with paclitaxel may therefore provide a new promising therapeutic treatment for lung cancer. |
format | Online Article Text |
id | pubmed-7365669 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-73656692020-08-05 Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer Zhang, Na Sun, Pan Jin, Haizhen Yang, Yuqin Zhao, Qingya Zhou, Lin Guo, Lili Yang, Xiaohua Lu, Liming Anticancer Drugs Preclinical Reports The role of histone deacetylases (HDACs) in lung cancer has been extensively studied. Inhibition of HDAC activities have been used as a new cancer treatment strategy. To date, many HDAC inhibitors have been shown to induce apoptosis and inhibit tumorigenesis. Chidamide (CS055) is a new member of HDAC inhibitors. In China, Chidamide has been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma. However, the efficacy of Chidamide in non-small cell lung cancer remains unclear. In this study, we used lung cancer primary cells and investigated the effects of Chidamide combined with paclitaxel on lung cancer. We found that Chidamide combined with paclitaxel effectively inhibited the expression and activity of HDAC in primary lung cancer cells, induced their apoptosis and blocked cell cycle. Chidamide combined with paclitaxel may therefore provide a new promising therapeutic treatment for lung cancer. Lippincott Williams & Wilkins 2020-04-16 2020-08 /pmc/articles/PMC7365669/ /pubmed/32701251 http://dx.doi.org/10.1097/CAD.0000000000000935 Text en Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/) (CC-BY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Preclinical Reports Zhang, Na Sun, Pan Jin, Haizhen Yang, Yuqin Zhao, Qingya Zhou, Lin Guo, Lili Yang, Xiaohua Lu, Liming Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer |
title | Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer |
title_full | Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer |
title_fullStr | Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer |
title_full_unstemmed | Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer |
title_short | Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer |
title_sort | chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer |
topic | Preclinical Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365669/ https://www.ncbi.nlm.nih.gov/pubmed/32701251 http://dx.doi.org/10.1097/CAD.0000000000000935 |
work_keys_str_mv | AT zhangna chidamidecombinedwithpaclitaxeleffectivelyreversestheexpressionofhistonedeacetylaseinlungcancer AT sunpan chidamidecombinedwithpaclitaxeleffectivelyreversestheexpressionofhistonedeacetylaseinlungcancer AT jinhaizhen chidamidecombinedwithpaclitaxeleffectivelyreversestheexpressionofhistonedeacetylaseinlungcancer AT yangyuqin chidamidecombinedwithpaclitaxeleffectivelyreversestheexpressionofhistonedeacetylaseinlungcancer AT zhaoqingya chidamidecombinedwithpaclitaxeleffectivelyreversestheexpressionofhistonedeacetylaseinlungcancer AT zhoulin chidamidecombinedwithpaclitaxeleffectivelyreversestheexpressionofhistonedeacetylaseinlungcancer AT guolili chidamidecombinedwithpaclitaxeleffectivelyreversestheexpressionofhistonedeacetylaseinlungcancer AT yangxiaohua chidamidecombinedwithpaclitaxeleffectivelyreversestheexpressionofhistonedeacetylaseinlungcancer AT luliming chidamidecombinedwithpaclitaxeleffectivelyreversestheexpressionofhistonedeacetylaseinlungcancer |